Company Overview

Innovating cures, shaping what's next

JW Therapeutics (HKEX: 2126) is a biotechnology company dedicated to advancing innovative cell immunotherapies.

Founded in 2016 in partnership with Juno Therapeutics*, the Company combines global expertise in cell therapy development with China's manufacturing capabilities to accelerate the research, development, manufacturing, and commercialization of innovative cell immunotherapy products, improving patient access to high-quality therapies in China and worldwide.

JW Therapeutics has established an integrated platform spanning scientific discovery, process development, manufacturing, quality management, and clinical application. Focusing on hematologic malignancies, solid tumors, and autoimmune diseases, the Company continues to advance a differentiated pipeline while building robust commercial manufacturing capabilities and a comprehensive quality management system.

Guided by the vision of "Innovating cures, shaping what's next.", JW Therapeutics is committed to expanding access to high-quality cell immunotherapies and bringing new hope to patients in China and around the world.

*Juno Therapeutics is an innovative biotechnology company specializing in cell therapy research and development and is currently a wholly owned subsidiary of Bristol Myers Squibb (BMS).

Scientific Innovation

Focused on advancing the frontiers of cell immunotherapy, we continuously drive differentiated technology innovation and translational research to explore new treatment possibilities across multiple disease areas.

Translational Excellence

We have established an integrated platform spanning process development, manufacturing, and quality management, ensuring product quality, safety, and accessibility through high standards of operational excellence.

Patient Value

Guided by patients' needs, we are committed to advancing the clinical application and standardized development of cell immunotherapies, enabling innovative treatments to benefit more patients.